Clinical Trials Browser

Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT01311713 2024-01-30

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Phase 1/2 Terminated

45 enrolled 16 charts

Tumor-Agnostic

Neoplasms

NCT06121557 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Other solid neoplasm

Solid Tumor

NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Phase 2 Recruiting

900 enrolled

Genitourinary

Neoadjuvant Therapy

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

52 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

55 enrolled

Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

NCT03227016 2021-01-27

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Phase 1 Unknown

30 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Phase 2 Completed

41 enrolled

Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2 Completed

43 enrolled

Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

CONVERT-HB1

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

VISIONARY

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

PD1 and PARP for Maintenance Therapy in NSLLC

DOMEC

Study in Patients With SCLC of Veliparib in Combination With Topotecan

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers